Trial Profile
A pilot study evaluating efficacy of IncobotulinumtoxinA (Xeomin) for Temporomandibular Joint Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial pain; Musculoskeletal pain; Temporomandibular joint dysfunction syndrome
- Focus Therapeutic Use
- 15 May 2017 New trial record
- 01 Apr 2017 Results published in the Annals of Otology, Rhinology and Laryngology